Innovation

A line chart ending in a paper airplane
Insights

R&D for new drugs to tackle AMR is a high-return investment for all EU member states

19 July 2024

Two recently-published papers predict high returns from a policy which incentivises the development of new antibiotics.

Insights

Using Target Product Profiles (TPPs) to improve diagnostic testing for cancer

10 June 2024

Tackling cancer is a major global priority. Early detection and diagnosis can help patients get timely access to treatment and dramatically improve cancer outcomes. This relies, in part, on the effective diagnostic tests.

Innovation for Health System Efficiency and Improvement
Publication

Innovation for Health System Efficiency and Improvement

20 November 2023

In this report, commissioned and funded by Gilead, we explore the role of innovation in developing healthcare system efficiency amid post-pandemic challenges. 

News

NGS testing for lung cancer across Europe still limited, despite clear case for adoption

10 July 2023

Our new report contains a wealth of evidence for clinical value and cost-saving potential of next-generation sequencing (NGS) testing in lung cancer, and recommends that increased uptake requires focus on reimbursement, national standardisation, and new infrastructure

Insights

Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?

15 February 2023

Gene therapies pose fresh challenges for discounting practice by HTA agencies. In this blog, we discuss why discounting is important for gene therapies, using a potential gene therapy for X-Linked Retinitis Pigmentosa (XLRP) as an example.

Insights

Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges

6 February 2023

During an engaging discussion of Professor Aidan Hollis’ prizewinning proposal with Professor Adrian Towse a range of potential benefits and remaining questions were explored.

News

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

25 January 2023

Entrants challenged to devise a globally applicable approach to fair pricing of medicines. Winning entry proposes de-linking the innovation reward payments from the price.

Insights

G7 Investments in New Antibiotics Would Pay Off – For Everyone

9 December 2022

Programs to incentivise antibiotic R&D are underway in the UK and under consideration in the US, EU, Canada, and Japan. We have assessed the benefits and costs to the members of the G7/EU and project that all G7/EU members would see big payoffs ranging from 11:1 in the UK to 28:1 for the US and Japan. Global returns from reducing the 1.27m people dying each year from AMR are even higher.

Insights

The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics

12 October 2022

In the third instalment in our blog series, we think about how the rest of the world can join the effort to stimulate a healthy market for new antibiotics….